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The prevalence of cognitive impairment and dementia caused by cerebrovascular disease is likely to increase with the global aging
population. Vascular contributions to cognitive impairment and dementia (VCID) is a wide spectrum term used to include a
diverse heterogeneous group of cognitive syndromes with vascular factors regardless of the cause of pathogenesis. VCID ranges
from mild cognitive impairment to full-blown dementia with vascular dementia (VaD) as the most severe stage. It is further
complexed by the coexistence of other forms of dementia such as Alzheimer’s disease (AD). Recent researches in the functions
of the neurovascular unit (NVU) suggest that dysfunction of the NVU might be the cause of primary vascular events in the brain
that leads to further neurodegeneration. In this review, we have briefly summarized various forms of VCID. There is currently no
standard therapy for VCID or dementia. Given the fact that Traditional ChineseMedicine (TCM) has gained popularity worldwide,
we also reviewed recent scientific and clinical findings on various antidementia TCM for the treatment of VCID, including Salvia
miltiorrhiza, Huperzia serrata, Ligusticum chuanxiong, Ginkgo biloba, Panax ginseng, and also TCM formula Sailuotong capsule
(SLT) and Fufangdanshen tablets (FFDS).
1. Introduction
Dementia, which describes a syndrome with a gradual
decline in cognitive functioning, is a spectrum term that
includes various forms of cognitive impairment especially
among the elderly of our society. In 2015, the World Health
Organization (WHO) estimated 47.5million people are living
with dementia worldwide, and the number is projected to be
tripled to 135.5 million by 2050 [1]. The overall prevalence of
dementia among people aged 60 years and above is between
5 and 10%, varying among different global regions [2, 3].
In 2010 in China, 9.19 million of people were living with
various forms of dementia, and the prevalence increases
quickly with age escalating from 2.6% at age 65–69 to 60.5%
at age 95–99 [4]. The most common type of dementia is
Alzheimer’s disease (AD), which accounts for 50–70% of all
cases registered, followed by VaD, which accounts for 25% [1,
2]. Age-related dementia is a major cause of disabilities in the
elderly. Apart from the financial burdens, the social stigma
associated with the loss of cognitive abilities and dependency
on others also causes psychological distress in patients as well
as their families. The epidemic scale of dementia poses one
of the biggest challenges on global public health systems and
the financial burden associated with the social care needed.
The pathogenesis of dementia is complex and it involves
the interactions between many different physiological sys-
tems. Traditionally, AD and VaD are classified clinically as
neuropathological and cerebrovascular disorders. However,
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patients with AD often have mixed etiologies with both
neurodegenerative and cerebrovascular pathologies [3, 5, 6].
Besides, ischemic or hemorrhagic cerebrovascular diseases
or cerebral lesions caused by cardiovascular origin are com-
monly associated with cognitive impairments [3, 5]. Cerebral
infarctions and alterations in brain blood vessels commonly
occurred in the elderly which are possibly due to age-related
degeneration and other diseases [7, 8]. Since the brain is
a highly perfused organ and requires a continuous blood
supply for its physiological functions, it is not surprising
that damage to the cerebral circulation are associated with
an increased risk of many types of dementia. In addition,
epidemiology evidence indicates that AD and VaD share
similar cardiovascular risk factors including apolipoprotein E
(APOE𝜀4), hypertension, hypercholesterolemia, obesity, and
diabetes [5, 9, 10], although the strength of the association
between AD and cardiovascular risk factors could be greatly
influenced by the designation of parameters, and further
evaluation is needed [11, 12]. Therefore, recent researches in
neurodegenerative disorders such as dementia and AD have
focused on understanding the interplay between vascular
dysfunctions and primary neurodegenerative processes. It is
also suggested that cerebrovascular pathologies may be pri-
mary causes as well as contributing factors in the progression
of cognitive impairment and dementia.
In this review, we have included an overview of the def-
initions of various forms of dementia with vascular origins,
the importance of the neurovascular unit (NVU), and the
preclinical and clinical investigations of using Traditional
Chinese Medicine (TCM) to treat and manage cognitive
decline and dementia. Management of vascular risks and
symptoms is the primary approaches in treating vascular
dementia, and TCM has proven ability to treat cardiovascu-
lar diseases and hypertension effectively [3, 13]. Moreover,
TCM formulations for the treatment of dementia-like and
memory disorders have been extensively documented in the
classical Chinese medical literature, including herbs such as
Salvia miltiorrhiza,Huperzia serrata, Ligusticum chuanxiong,
Ginkgo biloba, and Panax ginseng [14–16]. In a recent meta-
analysis study, it indicated that TCM exhibited comparable
efficacy and safety as Western medicine for improving the
cognitive and behavior functions of patients with vascular
cognitive impairment with no dementia [17]. Therefore, it is
proposed that TCM has great potential uses as preventive
strategies against dementia which can have positive impacts
on global public health.
2. Definitions of Vascular Dementia (VaD),
Vascular Cognitive Impairment (VCI), and
Alzheimer’s Disease (AD)
Dementia describes a group of syndromes relating to cog-
nitive decline. Clinical manifestation of different forms of
dementia exhibits different levels of impaired performance
in various cognitive domains, including memory, learning,
executive function, and behavioral changes (e.g., depressive
symptoms). Cognitive impairment ranges from mild to
severe declines in any cognitive domain. Alzheimer’s disease
(AD) is the most common form of dementia, followed by
VaD [1, 2]. In the literature, “VaD” is often used ambiguously
to describe a group of clinically similar cerebrovascular
disorders associated with multiple pathological features, such
as multi-infarcts, single infarcts, hemorrhages, white matter
hyperintensities. Moreover, the progression of the manifes-
tation of dementia is preceded by a prodromal stage in
which the patient experiences progressive cognitive decline
but is still able to maintain independent daily activities [5].
This has further led to the usage of the general terms, for
example, VCI or VCID, in order to include all cognitive
impairments caused by cerebrovascular abnormalities, which
could be quite confusing. Essentially, VCI or VCID is
used to include a diverse heterogeneous group of cognitive
syndromes with vascular origins regardless of the cause of
pathogenesis, ranging from mild cognitive impairment to
full-blown dementia, and VaD is the most severe stage [3,
8, 18]. The heterogeneity and complexity of VCI however
make it difficult for appropriate clinical characterization.
Currently there are no accepted pathological criteria for
clinical diagnosis for VCI, but identifiable subtypes of VCI
have been categorized. This classification system may be
useful for clinicians to diagnose for the prevention and the
treatment of cognitive dysfunctions.The characterization and
classification of VCI are beyond the scope of the present
article, and more detailed information could be found in
previous reviews [3, 19, 20]. In addition, AD and VaD
have traditionally been characterized as separate disorders
based on the clinical diagnostic criteria. However, the “pure”
form of AD or VaD is not commonly found; instead most
people with dementia have mixed pathologies. Besides, AD
frequently coexists with cerebrovascular abnormalities such
as alterations in vascular structures (e.g., cerebral amyloid
angiopathy, CAA) and cerebral infarctions. Accumulating
evidence suggested that AD and VaD have additive effects
and probably interact with each other. It has been suggested
that cerebrovascular dysfunction could play a role in the
development and progression of AD. Therefore, the vascular
component in the mixed pathology is particularly important
for the understanding of the pathogenies of dementia. In
the next section, we will give a very brief overview of the
major subtypes of VCI. Note that the categorization of VCI
described here does not mean to replace any existing clinical
criteria for the characterization of different types of VaD
but to offer a simplified overview for a better understanding
of various VCI terminologies, especially for nonclinician
researchers. The terms VCI and VCID are used interchange-
able in this article.
2.1. Major Subtypes of Vascular Contributions to Cognitive
Impairment (VCI). Many subtypes of VCI or VCID have
been described before. The disorder is sometimes clas-
sified according to the location of vascular lesions, the
causative vascular mechanisms, and their clinical manifes-
tations. Chronic cerebral ischemia and arteriosclerosis were
originally thought to be the cause of vascular contributed
dementia but later discovered that it is cerebral infarcts rather
than ischemia that causes dementia [21]. Therefore, we try to
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summarize the major subtypes of VaD according to the type
of infarcts exhibited. Similar clinical features of VaD subtypes
have been described under different names; therefore we also
try to include them into specific groups. In brief, the major
subtypes of VCI include vascular mild cognitive impairment
(VaMCI), multi-infarct dementia (MID), strategic-infarct
dementia (SID) (which is also commonly known as subcorti-
cal vascular dementia (SVD) or small vessel disease (SVD)),
poststroke dementia, and mixed dementia of AD and VaD.
SID (or SVD) accounts for over 40% of all VCI reported
[20, 21]. Recent studies also indicated that mixed dementia
particularly VaD in conjunction with AD is also commonly
observed among elderly people [20, 21].
2.1.1. VascularMild Cognitive Impairment (VaMCI). Demen-
tia is preceded by a stage in which mild cognitive decline
is first manifested in individuals without affecting care-free
daily independent activities. VaMCI is used to describe this
intermediate stage between normal cognition and dementia
caused by vascular diseases with the presence of cognitive
impairment but it is not severe enough to fit into the criteria
for VaD [22]. An equivalent stage occurring in AD is referred
to asmild cognitive impairment (MCI) and is used to identify
people who are at risk for the later amnestic stage of AD.
The prevalence of VaMCI is twice as much of VaD [22].
VaMCI is potentially treatable by management of vascular
risk factors and diseases [3, 22]. Moreover, VaMCI is usually
associated with other diseases such as heart failure, autoim-
munedisorders, and depression, and previous studies showed
that cognitive functions of patients could be improved with
respective treatments for these disorders with or without
specific treatment for VaMCI [22–24]. VaMCI is common
in stroke patients shortly after attacks, and in some patients
cognition may improve as part of the stroke recovery process
[25, 26].
2.1.2. Large-Vessels VaD:Multi-Infarct Dementia (MID). MID
is caused by the “synergistic effects” caused by multiple
vascular lesions (“multiple mini strokes”) in the brain irre-
spective of specific location or volume. The mini strokes
which disrupted the blood flow to the brain may occur
without noticeable clinical symptoms, and over time these
lead to irreversible injuries in the brain tissues. MID can be
diagnosed by brain imaging techniques such as computed
tomography (CT) and magnetic resonance imaging (MRI)
scan. MID usually affects people between the ages of 60–75
and is more common in men than in women. However, MID
is not the single most common type of VaD in elderly people;
instead patients are more likely to have mixed dementia with
both AD and VaD pathology (discussed later) [27].
2.1.3. Small-Vessels VaD: Subcortical Ischemic Vascular De-
mentia (SIVD). SIVD is caused by the occlusion of small pen-
etrating arteries which supply blood to the inner structures of
the brainwhich is recognized as Binswanger’s disease, lacunar
infarct (LACI), or small vessel disease (SVD). SIVD is also
known as silent brain infarction (SBI), and it is the most com-
mon type of VaD with 20–40% incidence in our community
[28, 29]. This disease can be diagnosed using brain imaging
methods, for example, CT and MRI scan. Hypertension is
the major risk factor for SVID, and it is therefore potentially
preventable and treatable [29]. The hereditary genetic vas-
culopathy Cerebral Autosomal-Dominant Arteriopathy with
Subcortical Infarcts and Leukoencephalopathy (CADASIL),
which causes 11% of lacunar stroke cases with leukoaraiosis
in middle-aged adults, is one of the best examples of small
vessel disease affecting mainly the small penetrating cerebral
and leptomeningeal arteries [30].
2.1.4. Strategic-Infarct Dementia (SID). It has been tradition-
ally recognized that single or few focal infarcts occurred
in some functionally important brain regions (“strategic”)
such as lesions in the thalamus, caudate nucleus, lenticular
nucleus, angular gyrus, and internal capsule. However, the
concept of strategic infarction is under reexamination with
larger prospective MRI studies to study the relationship
between the extent and location of lesions and the cognitive
networks [3].
2.1.5. Poststroke Dementia (PSD). Poststroke dementia
(PSD), or poststroke cognitive impairment includes any
type of dementia that occurs after stroke, irrespective of the
leading causes, which can be vascular, neurodegenerative,
or mixed. Having a stroke doubles the risk of dementia
development. The prevalence of PSD in patients is about
30%, which varies between age, races, diagnostic criteria, and
periods after stroke [31]. The underlying causes of cognitive
impairment after stroke are not known at present. It is
suggested that vascular lesions caused by ischemia/hypoxia
or hemorrhages, cerebral microbleeds, white matter lesions,
and neurodegenerative pathologies from other conditions
such as AD all contribute to and probably interact with each
other to the pathogenesis of PSD. Increasing age is a major
determinant of PSD development. It has been reported that
15% of stroke survivors at the age of 60–69 had new-onset
dementia, and the prevalence was greatly increased to 26%
at the ages 70 to 79 and 36% at the age over 80 years [31–34].
2.1.6. Mixed Dementia. Mixed dementia is a condition in
which abnormal features of more than one type of dementia
occur simultaneously in the brain, and over 44% of dementia
was in fact mixed dementia with a combination of AD and
VaD pathologies [35]. The coexistence of AD and vascular
lesions is particularly common in older patients. Clinically,
a spectrum of vascular diseases is related to the failure of
microvasculature functions to regulate cerebral circulation
and elimination of interstitial fluid and solutes in both AD
and VaD. In AD, abnormal accumulation of amyloid-beta
(A𝛽) in the brain arterial walls, a condition known as cerebral
amyloid angiopathy (CAA), leads to the weakening of the
brain blood vessel wall and increases the risk of hemorrhages
[36]. More recently, dementia research has focused on the
importance of the neurovascular unit (NVU) at the level
of cellular and molecular mechanisms (discussed later) [6,
30, 37]. Mixed dementia may also include cases of AD and
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VaD associated with any other disorders such as Parkinson’s
disease (PD) and dementia with Lewy bodies (DLB) [35].
The following shows general classification for cognitive
impairment with vascular components.
Pathological features includes white matter hyperintensi-
ties (WMHs), multiple or single infarcts, hemorrhages, alter-
ation of brain vessel structure, and cerebral hypoperfusion.
Vascular Mild Cognitive Impairment (VaMCI)
(i) Predementia stage: patients have cognitive decline
without affecting daily independent functioning
(ii) Symptoms: amnestic, lack of attention, expressive
language disorder, and visual depth perception
(iii) Diagnosis methods: brain imaging, cerebrospinal
fluid tests, and so forth
The following shows severe cognitive decline.
Vascular Dementia (VaD)
Large-vessel VaD
Multi-infarct dementia (MID)
(i) Caused by multiple infarcts (cortical and/
or subcortical) with synergistic effect irre-
spective of location or volume
(ii) Symptoms: getting lost, language problem,
apathy, performing difficulties, emotional
lability, and loss of social skills
(iii) Diagnosis methods: a neurological exam,
a history of stepwise mental decline, com-
puted tomography (CT) or magnetic reso-
nance imaging (MRI) scans, an electroen-
cephalogram, a transcranial Doppler, and
so forth
Small vessel VaD
Subcortical ischemic vascular dementia (SIVD)
(may also be known as Binswanger’s disease,
Lacunar infarct (LACI), silent brain infarc-
tion (SBI), small vessel disease (SVD) (e.g.,
CADASIL))
(i) Caused by occlusion of penetrating arteries
and thus reduction of blood supply to the
brain’s deep structures
(ii) Symptoms: sudden hemiparesis, pseudob-
ulbar palsy, small-stepped gait, urinary
incontinence, dysarthria, dementia, and
changes in effect including inappropriate
laughing or crying
(iii) Diagnostic methods: assessment of cog-
nitive deficits (criteria of clinical trial of
SIVD), CT or MRI, and so forth
Strategic-infarct dementia (SID)
(i) Caused by focal infarcts in functionally impor-
tant brain regions (concept of SID is under
reexamination)
(ii) Symptoms: mental deterioration, depression,
emotional lability, apathy, cognitive, and other
deficits
(iii) Diagnostic methods: MRI, CT, perfusion
SPECT, and so forth
Poststroke Dementia (PSD)
(i) Including any type of dementia that occurs after
stroke irrespective of causes
(ii) Symptoms: trouble with speaking and understanding,
trouble with seeing in one or both eyes, cognitive
impairment
(iii) Diagnostic methods: CT, PET, functional MRI, spec-
troscopy, and so forth
Mixed Dementia
(i) Coexistence of more than one type of dementia
(e.g., VaD, Alzheimer’s disease (AD), and Parkinson’s
disease (PD))
(ii) Symptoms: symptoms may vary, depending on the
type of disease, it may be similar to those of AD or
another specific type of dementia
(iii) Diagnostic methods: CT, MRI, and so forth
3. Cerebral Circulation, the Neurovascular
Unit (NVU), and VCI
The pathogenesis underlying VCI has remained elusive with
many complexities. However, vascular risk factors associated
with the cerebral circulation such as hypertension and stroke
are shared by many neurodegenerative diseases and are
associatedwith the development of dementia [5].The cerebral
circulation is responsible for one of the most important jobs
in the body to provide and regulate blood supply for the
highly energy demanding central nervous system. Given the
highly perfused nature of the brain, it is not surprising that
any disruption or dysfunction in the cerebral circulation will
lead to cognitive impairments. The brain is perfused by a
sophisticated network of cerebral blood vessels. The anatomy
and cellular organization of the cerebral vasculature have
been described in detail previously [38, 39] and it is briefly
introduced here.
The common carotid arteries carry blood from the heart
to the brain and branch into two pairs of carotid arteries
(the internal and external carotid arteries). The carotid
arteries then give rise to cerebral arteries which further
divide into pial arteries that run along the surface of the
cortex within the pia-arachnoid. As the pial arteries penetrate
into the parenchyma, they become progressively smaller,
becoming intracerebral arterioles and cerebral capillaries to
supply blood to the corresponding regions of the cerebral
cortex. Importantly, the structures and functions of the
vessels change significantly as they penetrate into the brain’s
inner structure. All cerebral vessels have a layer of highly
specialized endothelial cells (the blood-brain barrier, BBB)
that provide specific barrier functions to regulate the fluid
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Figure 1: Schematic illustration of the cellular structure of the neurovascular unit (NVU).Dysfunction of theNVUcauses blood-brain barrier
(BBB) disruption and leads to the degeneration of neurons and VCI.
and solute exchange between the brain and the blood.Thepial
arteries on the surface of cerebral cortex consist of a layer of
endothelial cells surrounded by 2-3 layers of smooth muscle
cells and an outer layer of perivascular nerves. The smooth
muscle layers are important for supporting the endothelium
and regulating vessels contractility, similar to the systemic
blood vessels. As the vessels penetrate in the brain and
become smaller intracerebral arterioles, the smooth muscle
layer becomes thinner and the vessels are completelywrapped
around by astrocytic end-feet and other glia cells. The
glia (including astrocytes, oligodendrocytes, and microglia)
become more and more important in the maintenance and
stabilities of the endothelium. As the vessels further progress
and become cerebral capillaries, their endothelial cells are
sealed by tight junctions, enveloped by pericytes (which
replace the smooth muscle layer), and then surrounded
by a continuous basement membrane (BM). End-feet of
perivascular astrocytes cover the brain capillaries BM and
act to integrate the communication between the endothelium
and neurons.
The integrated system within a cerebral capillary that is
responsible for microvascular homeostasis and neurovascu-
lar coupling (the correlation between local neuronal activity
and changes in blood flow or hyperemia) is now considered a
specialized functional unit known as the neurovascular unit
(NVU) (Figure 1). The current understandings of the multi-
cellular organization and functions of the NVU in normal
and disease conditions are well described in recent reviews
[6, 30, 39]. Essentially, the components of theNVU include all
the cells present within the brain capillary (brain endothelial
cells, astrocytes, pericytes, microglia, neurons, and circulat-
ing inflammatory cells) as well as the basal membrane and
endothelial glycocalyx (a network of membrane-bound pro-
teoglycans and glycoproteins covering the luminal-side of the
endothelium). It is proposed that vascular risk factors such
as hypertension and hypercholesterolemia damage the NVU
and lead to chronic hypoperfusion, hypoxia, inflammatory
activation, and oxidative stress. The formation of a hypoxic
microenvironment at the NVU also directly contributes to
inflammatory activation by regulating gene such as hypoxia-
inducible factor 1𝛼 (HIF1𝛼), which serves as inducer of other
genes involved in inflammatory response signaling. Tissue
hypoxia and inflammatory activation in neurodegenerative
diseases induce the NVU to undergo various cellular inter-
actions and adaptations in responses, exhibiting pathophys-
iological features such as blood flow perturbation, vascular
alterations, adaptive angiogenesis, vascular remodeling, BBB
permeabilization, loss of tight junction and/or adherens
junction proteins, endothelial injuries, pericytes retraction,
BM breakdown, neurovascular uncoupling, and neuronal
impairments. This highlights the association of the injury
at NVU and the disruption of cerebral microcirculation as
a crucial step in ischemic-hypoxic tissue damage leading
to neuronal degeneration and cognitive impairment. It is
suggested that dysfunction of the NVUmay participate in all
brain pathologies development, and the primarymicrovascu-
lar events may be etiological to neurological diseases, as well
as being involved in diseases manifestation. Epidemiological
studies have also provided strong evidence supporting that
the NVU dysfunction is closely related to some neurological
pathogenesis. For example, hypertension in animal models
causing brain vessel rarefaction and a reduction in capillary
density and microvessel formation [40]. In the hereditary
CADASIL disease of small cerebral arteries, the NVU has
been indicated as a predominant causative factor in the
pathogenic mechanism of the disease. Structural alterations
in the small penetrating cerebral and leptomeningeal arteries
in CADASIL caused by pathogenic mutations in NOTCH3
(Notch homolog 3) lead to NVU impairment, causing
cerebral blood flow reduction and subcortical ischemia,
with lacunar infarcts correlating with cognitive decline [30].
Recently, the NVU has also been proposed to play an impor-
tant part in the development of cognitive decline observed in
AD [30, 37, 41]. It is reported that dementia is more likely to
happen when vascular lesions coexist in AD patients. Apart
from cerebral amyloid angiopathy (CAA) (the accumulation
of amyloid-beta (A𝛽) in brain blood vessels), an increased
concentration of soluble A𝛽 peptides in the cerebral circu-
lation of AD patients is also observed [42]. The elevated
level of soluble A𝛽 causes oxidative stress, and the damage
on cerebral circulation induced by A𝛽 precedes cognitive
decline, thus suggesting that cerebrovascular dysfunction
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might be involved in the pathogenesis of cognitive impair-
ment [42]. All these observations emphasize the importance
of the interaction between vascular and neuronal systems in
the context of disease pathogenesis and imply the potential
of the NVU as a target for disease prevention, treatment, and
management.
4. Therapeutic Implications for VCI with
Traditional Chinese Medicine (TCM)
Currently there is no standardized treatment regimen for
VCI. Several pharmacological agents approved for AD (done-
pezil, galantamine, rivastigmine, and memantine, Table 1)
have been tested to treat patients with VaD with only modest
improvements on standard cognitive measures and failed
to achieve regulatory approvals [3]. Other antidementia
candidates for treating cerebral small vessel disease are also
developed (e.g., nimodipine, huperzine) [3]. Uncertainties
in diagnostic criteria and the measurements of cognitive
domains further pose challenges and hurdles to the progress
of drug research and development. Given the fact about the
long history of TCM development and uses, many Chinese
herbs have been identified for the potential treatment of
the dementia-like disorders [43]. VCI belongs to the cate-
gory of memory disorders according to TCM theories that
is known as jian wang (健忘) (“forgetfulness”) and dai
bing (呆病) (“dementia”) [16, 17]. Over the last decades,
many clinical trials were conducted in China to investigate
TCM for treatment of cognitive impairment and dementia.
Despite the enormous efforts involved, most of these trials
conducted were not well-designed with limitations such as
small sample size, the lack of being truly randomized, double-
blind, and placebo-controlled, and the incomplete cognitive
assessments dedicated for VaD [44]. Thus, the genuine
effectiveness of most TCM therapies assessed for treating
dementia remains to be verified. Nevertheless, these studies
provided a valuable resource for the search of potential
antidementia drugs and therapies [16, 17, 45]. In addition, the
most effective approach for VCI treatment is themanagement
of underlying vascular risk factors and prevention of further
cerebrovascular injury. Many TCM herbal ingredients have
proven abilities to prevent and treat cardiovascular diseases
andmanagement of hypertension and stroke. In the following
session, the experimental studies of the herbs frequently
reported for the treatment ofmemory disorders with vascular
origins are reviewed and discussed (Table 1).
4.1. Salvia miltiorrhiza. The dried root of Salvia miltiorrhiza,
also known as Danshen, is a widely used TCM for the
treatment and prevention of cardiovascular diseases (CVDs)
such as angina pectoris, myocardial infarction, and arte-
riosclerosis. According to TCM theory, Danshen promotes
blood flow and resolves blood stasis. Several registered
pharmaceutical products containing Danshen extracts such
as Danshen Dripping Pill and Fufang Danshen Tablet are
widely used in clinics in the China showing effectiveness
for treating CVDs [43]. The herbal extract of Danshen
contains water-soluble danshensu (DSS) and salvianolic acid
Table 1: Current therapeutic agents and TCM for the treatment
against VCI/dementia and their action targets/mechanisms.
Therapeutic agents Targets/mechanisms for VCI
Donepezil
Galantamine
Rivastigmine
Acetylcholinesterase (AChE)
inhibition
Memantine Noncompetitive NMDA receptorantagonist
Salvia miltiorrhiza
Antiplatelet aggregation,
anti-inflammation, and
antioxidative effects
Huperzia serrata Selective AChE inhibition
Ligusticum chuanxiong
Antiapoptosis, antioxidant,
anti-inflammation, antiplatelet,
and block calcium (Ca2+)
overload
Ginkgo biloba
Restoring mitochondrial
dysfunction, improving neuronal
energy supplement, improving
compromised hippocampal
neurogenesis and neuroplasticity,
inhibiting A𝛽 protein
aggregation, decreasing blood
viscosity, and enhancing
microperfusion
Panax ginseng
Antioxidant, antiplatelet,
antihyperlipidemic, stimulation
of NO production, improvement
in blood circulation, and
enhancement of vasomotor tone
Saffron Antioxidant and inhibitingserotonin reuptake in synapses
B (Sal B) and lipid-soluble tanshinone I (Tan I), tanshinone
IIA (Tan IIA), cryptotanshinone, and dihydrotanshinone.
DSS is the major component in Danshen which possesses
multiple pharmacological effects that are beneficial to the
cardiovascular system, including coronary artery dilatation,
antiarrhythmia, microcirculation improvement, protection
of myocardial ischemia/reperfusion injury, and antiplatelet
aggregation [46–48]. Danshen has been used for the preven-
tion and treatment of cerebral infarction and the underlying
mechanisms involved multiple pathways, including antihy-
potension, antiplatelet aggregation, and anti-inflammatory
and antioxidative effects [49]. Recent animal in vivo stud-
ies have also shown that DSS exhibited protection against
cerebral ischemic/reperfusion injury [50] and neuronal cyto-
toxicity against oxidative damage [51]. Diabetes is a vascular
risk factor shared by AD and VaD, and the spatial learning
and memory are impaired in diabetic animals. In cognitive
impaired model of streptozotocin-induced diabetic mice,
DSS administration ameliorated the learning and memory
deficits by attenuating advanced glycation end products-
(AGE-) mediated neuroinflammation [52]. The lipid-soluble
Tan IIA improved learning and memory deficits in a chronic
cerebral ischemia rat model in vivo by protection against
free radical insults and regulating the levels of glutamate
and 𝛾-aminobutyric acid (GABA) [53]. On the other hand,
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Sal B exerted various neuroprotective and anti-inflammatory
activities in vivo and in vitro [54].
4.2. Huperzia serrata. An alkaloid isolated from the Chi-
nese herb Huperzia serrata, Huperzine A, is a natu-
ral cholinesterase inhibitor that selectively inhibits acetyl-
cholinesterase activity and increases acetylcholine levels in
brain, thereby improving cognitive functions in patients with
dementia [55]. In fact, HuperzineA has been used for treating
AD and mild memory deficits since 1994 in the China
[55, 56]. In a randomized, double-blinded placebo-controlled
clinical trial with the participation of 78 patients who have
mild to moderate VaD, Huperzine A treatment significantly
improved the cognitive functions in these patients [57].
Furthermore, both animal and human safety evaluations have
demonstrated that Huperzine A is safe [58]. Comparing with
other acetyl cholinesterase inhibitors such as galantamine,
donepezil, and tacrine, Huperzine A showed a longer dura-
tion of action, better penetration of the blood-brain bar-
rier, higher oral bioavailability, and fewer adverse reactions
[59].
4.3. Ligusticum chuanxiong. Ligusticum chuanxiong is a
famous medicinal herb known for its therapeutic effects for
treating ischemic stroke and tetramethylpyrazine (TMP) is
the major active ingredient. TMP possesses many protective
cardiovascular effects, including protection of mitochondrial
functions, inhibition of lipid peroxidation by free radicals,
attenuating calcium (Ca2+) overload, maintaining calcium
homeostasis, inhibiting inflammatory reaction, improving
endothelial cell function, and inhibiting myocardial cell
apoptosis [60]. Besides, TMP inhibits angiogenesis [61],
platelet aggregation, and antithrombosis and ameliorates
microcirculation [47, 62]. An injectable formulation known
as Guanxinning Injection (or Danshen Chuanxiong Injec-
tion) which contains extracts of Danshen and Chuanxiong
in combination has displayed a high efficacy in treating
hypertension and other cardiovascular diseases [63]. Apart
from the beneficial cardiovascular effects, TMP is a potent
neuroprotective agent. Evidence from in vivo experiments in
rats with middle cerebral artery occlusion (MCAO) demon-
strated that TMP has potent neuroprotective effects against
ischemic brain injuries caused by transient focal cerebral
ischemia reperfusion [64–67]. It has been shown that TMP
effectively reduced the size of cerebral infarction and brain
edema, suppressed oxidative stress and inflammatory and
apoptotic responses [64, 66, 67], and could salvage neurolog-
ical functions, neuronal dendritic plasticity, and behavioral
disturbance in the MCAO stroke model in rats [65, 67]. In
another study with scopolamine-induced memory impair-
ment model in rat, TMP could also effectively reverse mem-
ory deficits and preserved postsynaptic protein synthesis by
restoring the impaired cAMP/PKA/CREB pathways [68].
Besides, TMP attenuated iron-induced oxidative damage and
apoptosis in rat cerebellar granule cells [69]. Derivatives of
TMP, known as TBN and TN-2, which was synthesized with
the addition of powerful free radical-scavenging nitrone moi-
ety (Figure 2), exhibited promising neuroprotective effects.
TBN exhibited stronger antioxidative properties without
affecting the thrombolytic activity of the parent TMP and
produced neuroprotection against ischemic brain injuries
in rat transient and permanent MCAO stroke models via
the prevention of Ca2+-mediated cellular damage caused
by Ca2+ influx and overload [70, 71]. Furthermore, TBN
protected and rescued dopaminergic neurons from 1-methyl-
4-phenylpyridinium- (MPP+-) and methyl-4-phenyl-1,2,3,6-
tetrahydropyridine- (MPTP-) or 6-hydroxyldopamine- (6-
OHDA-) induced damage in vitro and in vivo models of
Parkinson’s disease (PD) by the reduction of oxidative stress
plus increased cellular antioxidative defense capacities [72].
TN-2, which has two nitrone moieties, also exhibited potent
neuroprotective effects against 6-OHDA-induced neuro-
toxicity and MPTP/MPP+-induced dopaminergic neurons
damage [73, 74]. Another derivative of TMP, known as T-
006 (Figure 2), protected primary cortical neurons from
neurotoxicity as well as improvement in memory deficits in
APP/PS1 transgenic mice [75].
4.4. Ginkgo biloba. Ginkgo biloba is a widely cultivated tree
since ancient China with the sacred belief for its health-
promoting properties. The fruits and leaves of Ginkgo biloba
are used to treat various types of diseases and symptoms
such as atherosclerosis, diabetes, poor circulation, fatigue,
vertigo, tinnitus, and cognitive disorder [15]. A standard-
ized extract of Ginkgo biloba (EGb 761) has been shown
to exhibit potent antioxidative and antiplatelet effects and
could effectively reduce damage from cerebral ischemia
[76–81]. Besides, EGb 761 extract protected hippocampal
neuronal and neuroglia cells against damage and enhanced
the recovery of learning/memory impairments from cerebral
ischemia/reperfusion in mice and rats [79–83]. Furthermore,
the Ginkgo extract has been reported to improve memory
deficits and cognitive dysfunctions in various experimental
models of memory disorders such as chronic stress, aging,
and Parkinson’s disease (PD) [84–86]. Recently, EGb 761
has also been shown to enhance the functions and integrity
of cerebral microvascular endothelial cells under chronic
stress induced by hypoxia, hyperglycemia, or amyloid-beta
(A𝛽) protein [87, 88], suggesting that functions of the
neurovascular unit might play an important role in the
protective effects of EGb 761. Interestingly, various clinical
trials have reported the efficacy of EGb 761 in improving
the cognitive impairment of patients with AD and VaD [89–
92]. In a recent study of a 24-week randomized controlled
trial [92], once-daily preparation of EGb 761 was shown
to improve cognitive functions, neuropsychiatric symptoms,
and functional abilities in 333 patients with AD and 71 with
VaD. In the market, Ginkgo extract is developed into an
herbal supplement called Gingium which is for improving
mild to moderate age-related cognitive impairments and
alleviating symptoms of AD, VaD, and/or mixed dementia.
It is noted that despite the encouraging evidence of the
beneficial effects of Ginkgo biloba consumption in treating
VaD, the potential drug-drug interactions especially associ-
ated with long-term usage of Ginkgo extract required further
evaluation.
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4.5. Panax ginseng. The root of the Panax ginseng is well-
known for many health benefits and has been widely used to
promote physical strength and healthyminds. Ginseng and its
active pharmacological ingredients ginsenosides have been
shown to improve age-related memory and cognitive deficits;
their therapeutic effects for the treatments of cerebrovascular
diseases and neurodegenerative diseases have been reviewed
recently [93–95]. Several studies reported that total ginseng,
total saponins, and Rg1, Rb1, and Rg2 have neuroprotective
effects [96–99]. Rg1 promoted the proliferation of hip-
pocampal progenitor cells after transient global ischemia
experimental brain ischemia [99], whereas Rb1 has been
reported to protect hippocampal neurons against ischemia
[100]. In a recent study using a VaD rat model, Rg2 improved
neurological performance and memory ability of VaD rats
after cerebral ischemia reperfusion through the modulation
of antiapoptotic signaling pathways [98]. Results from the
experimental AD models have also demonstrated that gin-
seng extract and ginsenosides are effective in protecting and
alleviating neuronal damage [93]. Two clinical studies on
ginseng therapy for the treatment of AD reported a significant
improvement in cognitive performance [101, 102].
4.6. TCM Formulae for Treatment of VaD. In recent years,
various TCM formulae for the treatment of VaD have
been developed, for example, Sailuotong capsule (SLT) and
Fufangdanshen tablets (FFDS) [103, 104]. SLT is composed
of ginseng extract (ginseng total saponins), Ginkgo biloba
extract (Yinxingtong ester), and saffron extract (saffron total
glycosides). The therapeutic functions of SLT are yi-qi-huo-
xue and hua-yu-tong-luo according to the TCM theory. Phar-
macodynamics studies showed that SLT could significantly
improve neurological symptoms caused by focal cerebral
ischemia and improve learning andmemory ability in animal
models of VaD. In healthy adults, one-week consumption
of SLT improved both neurocognitive and cardiovascular
functions [103]. More recently, an international multicenter
phase II clinical trial of SLT in patients with mild tomoderate
VaD has been initiated in 2012 to 2014, and the clinical
results/outcomes will be available soon [105]. In recent phase
III clinical trial launched in 2016, which involved research
teams of Xiyuan Hospital of the China Academy of Chinese
Medical Sciences and the National Institute of Complemen-
tary Medicine at Western Sydney University, over 200 Aus-
tralians with dementia were recruited and participated in this
clinical trials, and results obtained from the pilot studies have
implicated the effectiveness of SLTuses in improving learning
and memory [106]. On the other hand, an ongoing double-
blind, randomized, parallel placebo-controlled clinical study
on the evaluation of efficacy and safety of FFDS (Radix
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Salvia miltiorrhiza formula tablets) for patients with mild
to moderate VaD has shown encouraging data on treating
cognitive symptoms in VaD patients [104].
5. Conclusions
VCI (or VCID) is a complex form of dementia, involving
both vascular and neurological aspects. The heterogeneity of
VCI and the coexistence of other forms of dementia such as
AD make it even harder for effective drug development and
clinical treatment. Recently, the important roles of the neu-
rovascular unit (NVU) in neurodegenerative diseases are rig-
orously studied. Unfortunately, there is no standard therapy
forVCI.MostWesternmedicines are target-oriented whereas
TCM offers therapeutic outcomes via holistic approaches
which are probably appropriate for treating VCI which
involved various factors. Evidence-basedTCMtherapies have
shown some promising results for treating the symptoms
of cognitive impairments. Therefore, TCM serves as a rich
resource for therapeutic developments for treating dementia,
and it will be of interest to further investigate the actions of
potential TCM ingredients on the functions of NVU.
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